Benzinga | Aug 31, 2020 05:07AM EDT

Chardan Capital Maintains Buy on Viking Therapeutics, Raises Price Target to $20

Chardan Capital analyst Michael Morabito maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $15 to $20.